Pandemic may affect regulation of CBD products, former FDA official says

Pandemic may affect regulation of CBD products, former FDA official says

CSP Daily News — a media outlet that covers issues affecting retail and convenience stores — recently published an interview with a former attorney for the U.S. Food and Drug Administration, who said the current pandemic likely will slow down regulation of CBD and hemp products.

Regardless of potential regulatory slowdowns, Asterra Labs voluntarily surpasses CBD industry standards in three critical ways:

  1. Our ingredients meet or exceed guidelines established by the United States Pharmacopeia (USP).
  2. We follow stringent current Good Manufacturing Practices (cGMP).
  3. We rely upon a completely independent outside laboratory to test all of our products for quality and purity, and to ensure that each one contains the amount of CBD stated on the package.

To read the article in its entirety, click here.

Back to all posts